The Impact of Preclinical Irreproducibility on Drug Development
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The development of novel therapeutics depends and builds upon the validity and reproducibility of previously published data and findings. Yet irreproducibility is pervasive in preclinical life science research and can be traced to cumulative errors or flaws in several areas, including reference materials, study design, laboratory protocols, and data collection and analysis. The expanded development and use of consensus‐based standards and well‐documented best practices is needed to both enhance reproducibility and drive therapeutic innovations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
Believe it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888
Policy: NIH plans to enhance reproducibility
Collins, F. S., & Tabak, L. A. (2014) · Nature · doi:10.1038/505612a · Cited by 1,247 · cited 3×
“Regarding the latter, some prominent researchers have suggested that the incentive structure of scientific publishing itself must change for the above reforms to become successful.(5) At the same time, explicitly tracking replication as a means of postpublication evaluation can assist researchers in identifying reliab…”
InfluentialVasilevsky, N. A., Brush, M. H., Paddock, H., Ponting, L., Tripathy, S. J., LaRocca, G. M., & Haendel, M. A. (2013) · PeerJ · doi:10.7717/peerj.148 · Cited by 271
Drug development and clinical trials—the path to an approved cancer drug
Rubin, E. H., & Gilliland, D. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.22 · Cited by 135
Cited by
The economics of reproducibility in preclinical research
Freedman, L. P., Cockburn, I. M., & Simcoe, T. S. (2015) · PLOS Biology · doi:10.1371/journal.pbio.1002165 · Cited by 1,055
“, PubMed Commons, PubPeer), data sharing, and open access publishing that accelerate the identification of irreproducible studies [4].”
BackgroundSelf-citationCummings, J., Ritter, A., & Zhong, K. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179901 · Cited by 176
Irreproducibility in Preclinical Biomedical Research: Perceptions, Uncertainties, and Knowledge Gaps
Jarvis, M. F., & Williams, M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.12.001 · Cited by 129
“Reproducibility in Biomedical Research Reports of the inability to reproduce findings in preclinical biomedical research are considered by many to be a major contributory factor to the lack of efficiency and productivity in drug development, as reflected in the disconnect between research funding and new drug approval…”
BackgroundInfluentialMichel, M. C., Murphy, T. J., & Motulsky, H. J. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.118927 · Cited by 127
Thermoneutrality, mice, and cancer: a heated opinion
Hylander, B. L., & Repasky, E. A. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.03.005 · Cited by 107
Metadata
- Authors
- Freedman, L., & Gibson, M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2014-12-02
- Volume
- 97
- Issue
- 1
- Pages
- 16-18
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1994156127
- Cited by
- 43
- References
- 5
- FWCI
- 8.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Impact of Preclinical Irreproducibility on Drug Development. https://app.cochat.ai/papers/10.1002/cpt.9
- The paper
- Freedman, L., & Gibson, M. (2015). The Impact of Preclinical Irreproducibility on Drug Development. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.